{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:03:57Z","timestamp":1758477837698,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["694913"],"award-info":[{"award-number":["694913"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Primary aldosteronism (PA) due to unilateral aldosterone-producing adenoma (APA) is preferentially treated by unilateral adrenalectomy (ADX), but little is known about the changes in lipid and glucose metabolism that may occur after ADX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We studied 19 non-diabetic patients who did not use lipid-lowering drugs with PA due to APA before and 6 months after unilateral ADX. Fasting plasma lipids, lipoprotein subfractions, branched-chain amino acids (BCAA), and GlycA, a pro-inflammatory glycoprotein biomarker, were measured by nuclear magnetic resonance (NMR) spectroscopy. The Lipoprotein Insulin Resistance (LP-IR) score, which is based on six lipoprotein variables, was calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In all patients, hyperaldosteronism was resolved after ADX. Body mass index and fasting plasma glucose were unchanged, but HbA1c increased (<jats:italic>p<\/jats:italic>\u2009=\u20090.002). Plasma triglycerides, large triglyceride-rich lipoprotein (TRL) cholesterol, and large TRL particles were increased (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), resulting in an increase in TRL size (<jats:italic>p<\/jats:italic>\u2009=\u20090.027). High-density lipoprotein size was decreased (<jats:italic>p<\/jats:italic>\u2009=\u20090.015). LP-IR scores (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) and total BCAA (<jats:italic>p<\/jats:italic>\u2009=\u20090.017) were increased, but GlycA remained unaltered.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Based on increases in LP-IR scores and BCAA, which each have been shown to predict new onset type 2 diabetes mellitus independent of conventional risk factors in the general population, this preliminary study suggests that diabetes risk is not improved but may even be increased after ADX for APA despite remission of PA.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s12020-020-02235-2","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T19:02:46Z","timestamp":1583348566000},"page":"420-426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lipoprotein insulin resistance score and branched-chain amino acids increase after adrenalectomy for unilateral aldosterone-producing adenoma: a preliminary study"],"prefix":"10.1007","volume":"68","author":[{"given":"Christian","family":"Adolf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika M. A.","family":"Berends","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margery A.","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin P. F.","family":"Dullaart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"2235_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1055\/s-0029-1246189","volume":"42","author":"M Reincke","year":"2010","unstructured":"M. Reincke, C. Meisinger, R. Holle, M. Quinkler, S. Hahner, F. Beuschlein, M. Bidlingmaier, J. Seissler, S. Endres, Participants of the German Conn\u2019s Registry. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn\u2019s Registry. Horm. Metab. Res. 42, 435\u2013439 (2010)","journal-title":"Horm. Metab. Res."},{"key":"2235_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1055\/s-0035-1565208","volume":"47","author":"H Remde","year":"2015","unstructured":"H. Remde, G. Hanslik, N. Rayes, M. Quinkler, Glucose metabolism in Primary Aldosteronism. Horm. Metab. Res. 47, 987\u2013993 (2015)","journal-title":"Horm. Metab. Res."},{"key":"2235_CR3","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1055\/s-0035-1565125","volume":"47","author":"M Reincke","year":"2015","unstructured":"M. Reincke, F. Beuschlein, Progress in primary aldosteronism: translation on the move. Horm. Metab. Res. 47, 933\u2013944 (2015)","journal-title":"Horm. Metab. Res."},{"key":"2235_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"S. Monticone, F. D\u2019Ascenzo, C. Moretti, T. Williams, F. Veglio, F. Gaita, P. Mulatero, Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6, 41\u201350 (2018)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2235_CR5","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1210\/jc.2019-00299","volume":"104","author":"J Gerards","year":"2019","unstructured":"J. Gerards, D. Heinrich, C. Adolf, C. Meisinger, W. Rathmann, L. Sturm, N. Nirschl, M. Bidlingmaier, F. Beuschlein, B. Thorand et al. Impaired glucose metabolism in primary aldosteronism is associated with cortisol cosecretion. J. Clin. Endocrinol. Metab. 104, 3192\u20133202 (2019)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2235_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1042\/cs1030425","volume":"103","author":"C Farquharson","year":"2002","unstructured":"C. Farquharson, A. Struthers, Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin. Sci. 103, 425\u2013431 (2002)","journal-title":"Clin. Sci."},{"key":"2235_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/cen.13891","volume":"90","author":"A Berends","year":"2019","unstructured":"A. Berends, E. Buitenwerf, E. Gruppen, W. Sluiter, S. Bakker, M. Connelly, M. Kerstens, R. Dullaart, Primary aldosteronism is associated with decreased low-density and high-density lipoprotein particle concentrations and increased GlycA, a pro-inflammatory glycoprotein biomarker. Clin. Endocrinol. 90, 79\u201387 (2019)","journal-title":"Clin. Endocrinol."},{"key":"2235_CR8","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1161\/HYPERTENSIONAHA.107.109439","volume":"51","author":"A Krug","year":"2008","unstructured":"A. Krug, M. Ehrhart-Bornstein, Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension 51, 1252\u20131258 (2008)","journal-title":"Hypertension"},{"key":"2235_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","volume":"5","author":"T Williams","year":"2017","unstructured":"T. Williams, J. Lenders, P. Mulatero, J. Burrello, M. Rottenkolber, C. Adolf, F. Satoh, L. Amar, M. Quinkler, J. Deinum et al. Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 5, 689\u2013699 (2017)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2235_CR10","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1007\/s00268-015-3197-z","volume":"39","author":"M Kaga","year":"2015","unstructured":"M. Kaga, T. Utsumi, T. Tanaka, T. Kono, H. Nagano, K. Kawamura, N. Kamiya, T. Imamoto, N. Nihei, Y. Naya et al. Risk of new-onset dyslipidemia after laparoscopic adrenalectomy in patients with primary aldosteronism. World J. Surg. 39, 2935\u20132940 (2015)","journal-title":"World J. Surg."},{"key":"2235_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12020-016-0983-9","volume":"54","author":"C Adolf","year":"2016","unstructured":"C. Adolf, E. Asbach, A. Dietz, K. Lang, S. Hahner, M. Quinkler, L. Rump, M. Bidlingmaier, M. Treitl, R. Ladurner et al. Worsening of lipid metabolism after successful treatment of primary aldosteronism. Endocrine 54, 198\u2013205 (2016)","journal-title":"Endocrine"},{"key":"2235_CR12","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1210\/jc.2012-3934","volume":"98","author":"E Fischer","year":"2013","unstructured":"E. Fischer, C. Adolf, A. Pallauf, C. Then, M. Bidlingmaier, F. Beuschlein, J. Seissler, M. Reincke, Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J. Clin. Endocrinol. Metab. 98, 2513\u201320 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2235_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cca.2016.06.012","volume":"459","author":"M Connelly","year":"2016","unstructured":"M. Connelly, E. Gruppen, J. Otvos, R. Dullaart, Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer. Clin. Chim. Acta 459, 177\u2013186 (2016)","journal-title":"Clin. Chim. Acta"},{"key":"2235_CR14","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/aje\/kwx016","volume":"186","author":"P W\u00fcrtz","year":"2017","unstructured":"P. W\u00fcrtz, A. Kangas, P. Soininen, D. Lawlor, G. Davey Smith, M. Ala-Korpela, Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -omic technologies. Am. J. Epidemiol. 186, 1084\u20131096 (2017)","journal-title":"Am. J. Epidemiol."},{"key":"2235_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1089\/met.2014.0050","volume":"8","author":"I Shalaurova","year":"2014","unstructured":"I. Shalaurova, M. Connelly, W. Garvey, J. Otvos, Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. Metab. Syndr. Relat. Disord. 8, 422\u2013429 (2014)","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"2235_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacl.2018.11.009","volume":"13","author":"J Flores-Guerrero","year":"2019","unstructured":"J. Flores-Guerrero, M. Connelly, I. Shalaurova, E. Gruppen, L. Kieneker, R. Dullaart, S. Bakker, Lipoprotein insulin resistance index, a high-throughput measure of insulin resistance, is associated with incident type II diabetes mellitus in the prevention of renal and vascular end-stage disease study. J. Clin. Lipido. 13, 129\u2013137 (2019)","journal-title":"J. Clin. Lipido."},{"key":"2235_CR17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2337\/dc14-0645","volume":"38","author":"R Mackey","year":"2015","unstructured":"R. Mackey, S. Mora, A. Bertoni, C. Wassel, M. Carnethon, C. Sibley, D. Goff Jr, Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis. Diabetes Care. 38, 628\u2013636 (2015)","journal-title":"Diabetes Care."},{"key":"2235_CR18","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jacl.2017.06.008","volume":"11","author":"P Harada","year":"2017","unstructured":"P. Harada, O. Demler, S. Dugani, A. Akinkuolie, M. Moorthy, P. Ridker, N. Cook, A. Pradhan, S. Mora, Lipoprotein insulin resistance score and risk of incident diabetes during extended follow-up of 20 years: the Women\u2019s Health Study. J. Clin. Lipido. 11, 1257\u20131267 (2017)","journal-title":"J. Clin. Lipido."},{"key":"2235_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.clinbiochem.2018.02.001","volume":"54","author":"J Wolak-Dinsmore","year":"2018","unstructured":"J. Wolak-Dinsmore, E. Gruppen, I. Shalaurova, S. Matyus, R. Grant, R. Gegen, S. Bakker, J. Otvos, M. Connelly, R. Dullaart, A novel NMR-based assay to measure circulating concentrations of branched-chain amino acids: Elevation in subjects with type 2 diabetes mellitus and association with carotid intima media thickness. Clin. Biochem. 54, 92\u201399 (2018)","journal-title":"Clin. Biochem."},{"doi-asserted-by":"publisher","unstructured":"J. Flores-Guerrero, M. Ost\u00e9, L. Kieneker, E. Gruppen, J. Wolak-Dinsmore, J. Otvos, M. Connelly, S. Bakker, R. Dullaart, Plasma branched-chain amino acids and risk of incident type 2 diabetes: results from the PREVEND Prospective Cohort Study. J. Clin. Med. 7 (2018). https:\/\/doi.org\/10.3390\/jcm7120513","key":"2235_CR20","DOI":"10.3390\/jcm7120513"},{"key":"2235_CR21","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"J Funder","year":"2016","unstructured":"J. Funder, R. Carey, F. Mantero, M. Murad, M. Reincke, H. Shibata, M. Stowasser, W. Young Jr, The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 1889\u20131916 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2235_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1530\/EJE-11-0287","volume":"165","author":"M Betz","year":"2011","unstructured":"M. Betz, C. Degenhart, E. Fischer, A. Pallauf, V. Brand, U. Linsenmaier, F. Beuschlein, M. Bidlingmaier, M. Reincke, Adrenal vein sampling using rapid cortisol assays n primary aldosteronism is useful in centers with low success rates. Eur. J. Endocrinol. 165, 301\u2013306 (2011)","journal-title":"Eur. J. Endocrinol."},{"key":"2235_CR23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/eci.12746","volume":"47","author":"R Ladurner","year":"2017","unstructured":"R. Ladurner, S. Sommerey, S. Buechner, A. Dietz, C. Degenhart, K. Hallfeldt, J. Gallwas, Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism. Eur. J. Clin. Investig. 47, 372\u2013377 (2017)","journal-title":"Eur. J. Clin. Investig."},{"key":"2235_CR24","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1373\/clinchem.2014.232918","volume":"61","author":"J Otvos","year":"2015","unstructured":"J. Otvos, I. Shalaurova, J. Wolak-Dinsmore, M. Connelly, R. Mackey, J. Stein, R. Tracy, GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin. Chem. 61, 714\u2013723 (2015)","journal-title":"Clin. Chem."},{"doi-asserted-by":"publisher","unstructured":"E. Gruppen, S. Kunutsor, L. Kieneker, B. van der Vegt, M. Connelly, G. de Bock, R. Gansevoort, S. Bakker, R. Dullaart, GlycA, a novel pro-inflammatory glycoprotein biomarker is associated with mortality: results from The PREVEND study and meta-analysis. J. Intern. Med. (2019). https:\/\/doi.org\/10.1111\/joim.12953","key":"2235_CR25","DOI":"10.1111\/joim.12953"},{"key":"2235_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1365-2362.2007.01756.x","volume":"37","author":"R Dullaart","year":"2007","unstructured":"R. Dullaart, G. Dallinga-Thie, B. Wolffenbuttel, A. van Tol, CETP inhibition in cardiovascular risk management: a critical appraisal. Eur. J. Clin. Investig. 37, 90\u201398 (2007)","journal-title":"Eur. J. Clin. Investig."},{"key":"2235_CR27","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1194\/jlr.M005348","volume":"51","author":"J Krikken","year":"2010","unstructured":"J. Krikken, R. Gansevoort, R. Dullaart; PREVEND Study Group, Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease. J. Lipid Res. 51, 1982\u20131990 (2010)","journal-title":"J. Lipid Res."},{"key":"2235_CR28","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0895-7061(01)02141-0","volume":"14","author":"T Hirano","year":"2001","unstructured":"T. Hirano, G. Yoshino, K. Kashiwazaki, M. Adachi, Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. Am. J. Hypertens. 14, 908\u2013913 (2001)","journal-title":"Am. J. Hypertens."},{"key":"2235_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1161\/CIRCRESAHA.107.151746","volume":"101","author":"N Iwamoto","year":"2007","unstructured":"N. Iwamoto, S. Abe-Dohmae, M. Ayaori, N. Tanaka, M. Kusuhara, F. Ohsuzu, S. Yokoyama, ATP-binding cassette transporter A1 gene transcription is downregulated by activator protein 2alpha. Doxazosin inhibits activator protein 2alpha and increases high-density lipoprotein biogenesis independent of alpha1-adrenoceptor blockade. Circ. Res. 101, 156\u2013165 (2007)","journal-title":"Circ. Res."},{"key":"2235_CR30","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1136\/jim-2016-000102","volume":"64","author":"A Srivastava","year":"2016","unstructured":"A. Srivastava, B. Adams-Huet, G. Vega, R. Toto, Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. J. Investig. Med. 64, 1102\u20131108 (2016)","journal-title":"J. Investig. Med."},{"key":"2235_CR31","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrendo.2014.171","volume":"10","author":"C Lynch","year":"2014","unstructured":"C. Lynch, S. Adams, Branched-chain amino acids in metabolic signaling and insulin resistance. Nat. Rev. Endocrinol. 10, 723\u2013736 (2014)","journal-title":"Nat. Rev. Endocrinol."},{"key":"2235_CR32","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.metabol.2013.01.007","volume":"62","author":"B Batch","year":"2013","unstructured":"B. Batch, S. Shah, C. Newgard, C. Turer, C. Haynes, J. Bain, M. Muehlbauer, M. Patel, R. Stevens, L. Appel et al. Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness. Metabolism 62, 961\u2013969 (2013)","journal-title":"Metabolism"},{"doi-asserted-by":"publisher","unstructured":"M. Yoon, The emerging role of branched-chain amino acids in insulin resistance and metabolism. Nutrients. (2016). https:\/\/doi.org\/10.3390\/nu8070405","key":"2235_CR33","DOI":"10.3390\/nu8070405"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02235-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-020-02235-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02235-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T15:03:00Z","timestamp":1666018980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-020-02235-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["2235"],"URL":"https:\/\/doi.org\/10.1007\/s12020-020-02235-2","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"type":"print","value":"1355-008X"},{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2020,3,4]]},"assertion":[{"value":"4 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MAC is an employee of LabCorp. The rest of the authors declare that they do not have anything to disclose regarding conflict of interest with respect to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}